Plasma Cannabinoid Pharmacokinetics following Controlled Oral Δ9-Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration
Erin L Karschner(National Institutes of Health), Marilyn A. Huestis(Smithsonian Institution), Robert S. Goodwin(National Institute on Drug Abuse), W. D. Darwin(National Institutes of Health), Stephen Wright(GW Pharmaceuticals (United Kingdom))
Cited by 226
Related Papers
Human Cannabinoid Pharmacokinetics
|Chemistry & Biodiversity|2007|1.1k
Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications
|Drug and Alcohol Dependence|2014|697
Neuropsychological Performance in Long-term Cannabis Users
|Archives of General Psychiatry|2001|656
Cannabis Effects on Driving Skills
|Clinical Chemistry|2012|613
Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: Influence of ionization type, sample preparation, and biofluid
|Journal of the American Society for Mass Spectrometry|2003|599